SI2743348T1 - Novo protitelo proti-humanemu ngf - Google Patents

Novo protitelo proti-humanemu ngf Download PDF

Info

Publication number
SI2743348T1
SI2743348T1 SI201231222T SI201231222T SI2743348T1 SI 2743348 T1 SI2743348 T1 SI 2743348T1 SI 201231222 T SI201231222 T SI 201231222T SI 201231222 T SI201231222 T SI 201231222T SI 2743348 T1 SI2743348 T1 SI 2743348T1
Authority
SI
Slovenia
Prior art keywords
fab
fragment
human ngf
antibody
polynucleotide
Prior art date
Application number
SI201231222T
Other languages
English (en)
Inventor
Masazumi Kamohara
Hirotsugu Tanaka
Yukari Koya
Jun Takasaki
Atsuo Yonezawa
Eiji Yoshimi
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of SI2743348T1 publication Critical patent/SI2743348T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (6)

  1. NOVO PROTITELO PROTI-HUMANEMU NGF PATENTNI ZAHTEVKI
    1. Fab' fragment protitelesa proti humanemu NGF, ki obsega: fragment težke verige, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO:10, SEQ ID NO:14 ali SEQ ID NO:16; in lahko verigo, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO: 12, kjer je Fab 'fragment konjugiran s polietilenglikolom.
  2. 2. Fab' fragment po zahtevku 1, ki obsega: fragment težke verige, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO:14; in lahka veriga, ki sestoji iz aminokislinske sekvence, prikazane s SEQ ID NO: 12, kjer je Fab 'fragment konjugiran s polietilenglikolom.
  3. 3. Metoda za pripravo Fab' fragmenta protitelesa proti-humanemu NGF, ki obsega izražanje Fab' fragmenta protitelesa proti-humanemu NGF z gojenjem gostiteljske celice, izbrane iz skupine, ki jo sestavljajo (a) in (b), (a) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 1 in polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta po zahtevku 1; in (b) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 1 in z ekspresijskim vektorjem ki obsega polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta v skladu po zahtevku 1, in konjugiranje Fab' fragmenta protitelesa proti-humanemu NGF s polietilen glikolom.
  4. 4. Metoda za pripravo Fab' fragmenta protitelesa proti-humanemu NGF, ki obsega izražanje Fab' fragmenta protitelesa proti-humanemu NGF z gojenjem gostiteljske celice, izbrane iz skupine, ki jo sestavljajo (a) in (b), (a) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 2 in polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta po zahtevku 2; in (b) gostiteljsko celico, transformirano z ekspresijskim vektorjem, ki obsega polinukleotid, ki obsega sekvenco, ki kodira fragment težke verige Fab' fragmenta po zahtevku 2 in z ekspresijskim vektorjem ki obsega polinukleotid, ki obsega sekvenco, ki kodira lahko verigo Fab' fragmenta v skladu po zahtevku 2, in konjugiranje Fab' fragmenta protitelesa proti-humanemu NGF s polietilen glikolom.
  5. 5. Fab' fragment protitelesa proti humanemu NGF proizveden po postopku po zahtevku 3.
  6. 6. Fab' fragment protitelesa proti humanemu NGF proizveden po postopku po zahtevku 4.
SI201231222T 2011-08-11 2012-08-10 Novo protitelo proti-humanemu ngf SI2743348T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトｎｇｆ抗体
EP12821758.5A EP2743348B1 (en) 2011-08-11 2012-08-10 Novel anti-human ngf antibody

Publications (1)

Publication Number Publication Date
SI2743348T1 true SI2743348T1 (sl) 2018-04-30

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231222T SI2743348T1 (sl) 2011-08-11 2012-08-10 Novo protitelo proti-humanemu ngf

Country Status (28)

Country Link
US (2) US8986952B2 (sl)
EP (1) EP2743348B1 (sl)
JP (1) JP5376095B2 (sl)
KR (1) KR101999867B1 (sl)
CN (1) CN103748222B (sl)
AR (1) AR087506A1 (sl)
AU (1) AU2012293161B2 (sl)
BR (1) BR112014002576B1 (sl)
CA (1) CA2841181C (sl)
CY (1) CY1119914T1 (sl)
DK (1) DK2743348T3 (sl)
EA (1) EA024292B1 (sl)
ES (1) ES2663968T3 (sl)
HR (1) HRP20180155T1 (sl)
HU (1) HUE036079T2 (sl)
IL (1) IL230797A (sl)
IN (1) IN2014CN00614A (sl)
LT (1) LT2743348T (sl)
ME (1) ME02944B (sl)
MX (1) MX351273B (sl)
NO (1) NO2743348T3 (sl)
PL (1) PL2743348T3 (sl)
PT (1) PT2743348T (sl)
RS (1) RS56876B1 (sl)
SI (1) SI2743348T1 (sl)
TW (1) TWI554519B (sl)
WO (1) WO2013022083A1 (sl)
ZA (1) ZA201400741B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
JP6700620B2 (ja) * 2015-05-22 2020-05-27 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
CN108883177A (zh) * 2016-03-25 2018-11-23 安斯泰来制药株式会社 含有PEG化抗人NGF抗体Fab’片段的药物组合物
CN109929035B (zh) * 2017-12-15 2022-06-28 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002096458A1 (en) 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI1575517T1 (sl) 2002-12-24 2012-06-29 Rinat Neuroscience Corp Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
MXPA06000583A (es) 2003-07-15 2006-03-30 Amgen Inc Anticuerpos neutralizantes anti-ngf humano como inhibidores selectivos de la via del ngf.
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0606933B8 (pt) 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
SI2187964T1 (sl) 2007-08-10 2015-01-30 Regeneron Pharmaceuticals, Inc. Visokoafinitetna humana protitelesa proti humanemu živčnemu rastnemu faktorju
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
PL2206707T3 (pl) 2007-10-24 2015-01-30 Astellas Pharma Inc Związek azolokarboksamidowy lub jego sól
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Also Published As

Publication number Publication date
TW201319086A (zh) 2013-05-16
EP2743348B1 (en) 2018-01-10
LT2743348T (lt) 2018-05-10
BR112014002576A2 (pt) 2021-01-12
US20140155582A1 (en) 2014-06-05
CN103748222A (zh) 2014-04-23
WO2013022083A1 (ja) 2013-02-14
MX351273B (es) 2017-10-06
EP2743348A1 (en) 2014-06-18
CY1119914T1 (el) 2018-06-27
IN2014CN00614A (sl) 2015-04-03
AR087506A1 (es) 2014-03-26
HUE036079T2 (hu) 2018-06-28
IL230797A (en) 2017-06-29
HRP20180155T1 (hr) 2018-03-23
AU2012293161A1 (en) 2014-02-06
CA2841181A1 (en) 2013-02-14
PT2743348T (pt) 2018-02-23
CA2841181C (en) 2022-01-25
MX2014001627A (es) 2014-05-28
BR112014002576B1 (pt) 2022-08-23
KR101999867B1 (ko) 2019-07-12
EP2743348A4 (en) 2015-04-29
IL230797A0 (en) 2014-03-31
NO2743348T3 (sl) 2018-06-09
CN103748222B (zh) 2015-07-22
PL2743348T3 (pl) 2018-04-30
JP5376095B2 (ja) 2013-12-25
TWI554519B (zh) 2016-10-21
JPWO2013022083A1 (ja) 2015-03-05
ZA201400741B (en) 2014-11-26
RS56876B1 (sr) 2018-04-30
ME02944B (me) 2018-04-20
US20150218265A1 (en) 2015-08-06
US8986952B2 (en) 2015-03-24
AU2012293161B2 (en) 2017-04-27
ES2663968T3 (es) 2018-04-17
DK2743348T3 (en) 2018-02-26
EA201490433A1 (ru) 2014-05-30
EA024292B1 (ru) 2016-09-30
KR20140047116A (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
SI2743348T1 (sl) Novo protitelo proti-humanemu ngf
HRP20201505T1 (hr) Široko neutralizirajuća anti-hiv protutijela
NZ611468A (en) Humanized antibodies to liv-1 and use of same to treat cancer
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
NZ706377A (en) Il-6 antagonists and uses thereof
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2013141956A (ru) Антитело против ксф-1r
WO2011113019A3 (en) Ctla4 proteins and their uses
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
WO2013041845A3 (en) Animals, repertoires & methods for the production of human antibodies
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ714516A (en) Human antibodies to clostridium difficile toxins
RU2013135175A (ru) Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
PH12019501104A1 (en) Novel anti-human muc1 antibody fab fragment
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
MY177098A (en) Novel anti-human tslp receptor antibody
EA201400447A1 (ru) АНТИТЕЛА К CD1d
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.